EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double‐Blind Randomized Placebo‐Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality

Jurriaan F M Strous iD, Gijs H J Roelandt, Jens H van Dalfsen, Jeanine Kamphuis, Radboud M Marijnissen, Robert A Schoevers iD

International Journal of Methods in Psychiatric Research · 2025

DOI: 10.1002/mpr.70044 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift International Journal of Methods in Psychiatric Research, 2025. Verfasst von Jurriaan F M Strous und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Ketamine, Midazolam, Suicidal Ideation, Outcome Assessment, Health Care. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Suicidality is a transdiagnostic entity in patients with and without psychiatric disorders. Ketamine is a novel treatment for treatment‐resistant depression with favorable effects on related suicidality in this population. Little is known about the effects of ketamine on suicidality as a distinct phenomenon.

Objective

To assess whether a dose of 75 mg intranasal (IN) ketamine reduces acute suicidality relative to a 4 mg intranasal dose of the active placebo midazolam, 180 min after administration. Methods/design A double‐blind randomized placebo‐controlled trial ( N = 100) will assess the efficacy of fixed‐dose IN racemic ketamine in patients presenting with acute suicidality, regardless of psychiatric diagnosis. Participants receive a single IN dose of either racemic ketamine (75 mg) or midazolam (4 mg) along with treatment as usual. The primary outcome is the reduction in suicidal ideation as measured by the Beck Scale for Suicide Ideation (BSSI) at 180 min. Secondary outcomes include depression severity with the Montgomery Åsberg Depression Rating Scale (MADRS) and tolerability with the Systematic Assessment for Treatment Emerging Effects (SAFTEE) as well as blood‐based and neuroimaging markers.

Discussion

This study design considers key aspects such as patient selection, ketamine formulation, clinical management, and the follow‐up time points. Potential risks, limitations, and future considerations are additionally discussed. Trial Registration EudraCT 2020‐002905‐24, registered 6 October 2021

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineMidazolamSuicidal IdeationOutcome Assessment, Health CareHumansDouble-Blind MethodAdministration, IntranasalAdultMaleFemaleMiddle AgedYoung AdultRandomized Controlled Trials as TopicAdolescentEquivalence Trials as Topic

Stichwörter der Autor:innen

ketaminerandomized controlled trialsuicidality

Substanzen

KetamineMidazolam

Autor:innen und Institutionen

  • Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Lentis Mental Health Care, Groningen, the Netherlands.

ORCID-Profile: Jurriaan F M Strous, Robert A Schoevers

Förderung

  • ZonMw

Zitieren

APA

Strous, J. F. M., Roelandt, G. H. J., van Dalfsen, J. H., Kamphuis, J., Marijnissen, R. M., & Schoevers, R. A. (2025). The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double‐Blind Randomized Placebo‐Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality. International Journal of Methods in Psychiatric Research. https://doi.org/10.1002/mpr.70044

Vancouver

Strous JFM, Roelandt GHJ, van Dalfsen JH, Kamphuis J, Marijnissen RM, Schoevers RA. The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double‐Blind Randomized Placebo‐Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality. International Journal of Methods in Psychiatric Research. 2025. doi:10.1002/mpr.70044

BibTeX
@article{Strous2025,
  author = {Strous, Jurriaan F M and Roelandt, Gijs H J and van Dalfsen, Jens H and Kamphuis, Jeanine and Marijnissen, Radboud M and Schoevers, Robert A},
  title = {The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double‐Blind Randomized Placebo‐Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality},
  journal = {International Journal of Methods in Psychiatric Research},
  year = {2025},
  doi = {10.1002/mpr.70044}
}
Kostenlos starten →